of foscarnet are nephrotoxicity and neurotoxicity. [6][7][8][9] However, it causes little or no myelosuppression. The limited clinical experience to date suggests that foscarnet prophyCytomegalovirus (CMV) disease can be prevented by administration of ganciclovir prophylactically postlaxis is less effective than ganciclovir in preventing CMV infection and disease, and significant nephrotoxicity occurs transplant. However, up to 30% of patients discontinue use of ganciclovir as a result of profound neutropenia in up to 50% of patients. [10][11][12] To evaluate the safety and activity of foscarnet for CMV prophylaxis, we used this and may subsequently develop CMV infections while unprotected. To prevent reactivation of CMV, we drug as an alternative to ganciclovir for patients who could not receive ganciclovir because of delayed engraftment or administered foscarnet to 39 adults unable to receive ganciclovir due to delayed engraftment or ganciclovirganciclovir-induced neutropenia. The study end-points include CMV excretion, CMV disease, CMV-related induced neutropenia. Twenty-four (62%) of the patients had received T cell-depleted marrow transplants. Fosmortality, and toxicity. carnet sodium 60 mg/kg i.v. daily was continued until the neutropenia resolved, at which time ganciclovir was resumed. CMV prophylaxis commenced at a median of Patients and methods 28 days following transplantation. Median time to initiation of foscarnet was day 60 post-transplant, and Patients the median duration of treatment was 22 days. FoscarThirty-nine adults transplanted between November 1991 net was well-tolerated. Six (15%) patients had CMV and November 1994 who received either marrow (38) or detected while receiving prophylaxis, and CMV-related blood stem cells (one) from allogeneic donors were mortality was 5%. Foscarnet is a safe and effective enrolled on a non-randomized, open-label, standard practice agent for prevention of CMV disease in allogeneic transprotocol utilizing foscarnet sodium at our institution. plant recipients unable to receive ganciclovir.
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Minimum follow-up at the time of the analysis was 6
T cell-depleted transplants 24
months. CMV-related mortality was calculated by the CMV serology (patient/donor) method of Kaplan and Meier.
Results

Foscarnet prophylaxis engraftment. Upon discontinuation of acyclovir, ganciclovir
Nine patients (23%) received foscarnet as initial prophywas resumed at 5 mg/kg i.v. three to five times per week laxis because of delayed engraftment. The other 30 patients and continued until day 100. Intravenous immunoglobulin were switched from ganciclovir to foscarnet for ganciclo-(IVIG) 500 mg/kg i.v. was administered weekly until day vir-induced neutropenia. The median ANC in patients with 100 to all patients. All blood products were CMV-seronegganciclovir-induced neutropenia was 0.6 × 10 9 /l. Prophyative and/or filtered. Urine and peripheral blood buffy coat laxis for CMV was initiated at a median of 28 days (range cells were collected pre-transplant and at weekly intervals 16-51) following transplantation. Foscarnet was started at to day 100. The samples were tested for CMV by standard a median of 60 days (range 21-91) post-transplant and conculture and shell vial assay. For diagnosis of CMV disease, tinued for a median of 22 days (range 7-71). bronchoalveolar lavage fluid or tissue biopsies were similarly cultured. Tissue biopsies and autopsy specimens were also examined by light microscopy and immunocytochemiToxicity of foscarnet stry or by in situ hybridization for CMV. Patients who Renal toxicity was mild (Table 2 ). There was no significant developed CMV infection or disease were treated with gandifference in the median increase in creatinine in patients ciclovir 5 mg/kg i.v. every 12 h or foscarnet 60 mg/kg i.v.
receiving amphotericin B in comparison to those who did every 8 h for 14-21 days. IVIG was administered every not. Nausea and vomiting, which is not well reported, other day for patients who developed CMV pneumonia. occurred in 15% of patients despite aggressive anti-emetic Granulocyte colony-stimulating factor 5 g/kg/day was treatment. No seizures occurred in patients receiving administered subcutaneously when patients absolute neuprophylactic foscarnet. In the three patients with significant trophil count fell to less than 1.5 × 10 9 /l while receiving tremors, serum calcium and magnesium levels were within ganciclovir prophylaxis. for 3 days after growth factor discontinuation or until day
100. When neutropenia resolved and foscarnet was stopped, ganciclovir was resumed at 5 mg/kg i.v. five times per week
Survival
Thirty-two of the 39 patients (82%) were alive at day 100. Actuarial survivals at day 100 and day 180 post transplantation are 79% (95% CI 67-92%) and 54% (95% CI 38-70%), respectively (Figure 2 ). Six of the seven patients who died had received T cell-depleted marrow transplants. The causes of death included disseminated CMV with or without fungal infection (two patients), disseminated Aspergillus (two patients), graft failure (one patient), relapse (one patient), and adenovirus (one patient). The two patients with disseminated CMV disease at autopsy had steroidrefractory GVHD; however, the primary causes of death were CMV pnuemonitis and CMV hepatitis. geneic BMT.
1,4,5 Several randomized controlled studies have shown that ganciclovir prophylaxis decreases the incidence and severity of CMV disease.
1,5 These benefits are offset by the drug-associated neutropenia which occurs in normal limits. Foscarnet was discontinued in only two 30-60% of patients. 1, 5 In the study by Winston et al, 5 8% patients (5%), both due to renal toxicity: one of these was of patients who discontinued prophylactic ganciclovir secreceiving amphotericin B at 1 mg/kg/day and the other ondary to neutropenia developed serious CMV disease and patient had liver failure.
Prophylaxis failures
Six of the 39 patients (15%) had CMV detected by culture, shell vial assay, biopsy or autopsy while receiving prophylaxis with either ganciclovir or foscarnet; four had CMV infection and two had disease. The actuarial risks of CMV infection at day 100 and day 180 post-transplantation are 13% (95% CI 2-27%) and 20% (95% CI 6-33%), respectively (Figure 1) . Patient characteristics are included in Table 3 . Five of 13 patients who were CMV seropositive pretransplant with CMV seronegative donors failed prophylaxis. Five of the six patients had received ganciclovir at a dose of 5 mg/kg three times per week. The two patients with CMV disease identified at autopsy had no detectable excretion of CMV prior to death. Of the four patients with CMV infection, two were receiving daily foscarnet at the time of CMV detection and the other two were receiving ganciclovir. All were treated with full-dose foscarnet or no recurrence of CMV infection. the incidence of infection was not assessed. In high-risk aminoglycosides and cyclosporine. The gastrointestinal and neurological complications were also acceptable in our patients, an alternative to ganciclovir would be beneficial. Previous studies utilizing foscarnet for CMV prophylaxis investigation. Only 5% of patients required drug discontinuation for toxicity. suggest it is effective in clearing CMV infection and reducing the risk of CMV disease. In our experience, using fosFoscarnet was successfully given in an ambulatory setting via an Intermate pump. As mentioned previously, care carnet for patients unable to receive ganciclovir prophylaxis, only 15% developed CMV infection and 5% was taken to maintain adequate hydration either orally or via intravenous fluids. The ability to administer this agent developed CMV disease.
The small sample sizes in the other studies published in an outpatient setting makes it an acceptable alternative to ganciclovir. make it difficult to evaluate the efficacy of foscarnet. The relatively low rate of infection seen in our study is compaOur goal in this investigation was not to compare foscarnet to ganciclovir but rather to evaluate the efficacy and rable to rates reported by Goodrich et al 1 and Winston et al 5 in their evaluations of ganciclovir prophylaxis. 1, 5 This tolerability of foscarnet in high-risk patients where maintenance of CMV prophylaxis is critical. We conclude that is despite the fact that in our study 62% received T celldepleted marrow grafts and almost half were unrelated foscarnet is an effective and safe alternative to ganciclovir for CMV prophylaxis in high-risk allogeneic marrow donor marrow recipients, a subset of patients at higher risk for complications from CMV. This is significant because recipients. However, randomized, comparative studies between ganciclovir and foscarnet are necessary to evaluate in the Goodrich study, patients were not eligible if they received T cell-depleted transplants. In the Winston study, better the prophylactic and treatment roles of these agents in specific BMT populations. only 39 and 18% of the patients were T cell depleted or matched unrelated donor recipients, respectively. In addition, patients were eligible for the ganciclovir prophylaxis studies only if they had engrafted, while 23% of our References patients experienced delayed engraftment and therefore required foscarnet as initial prophylaxis. It should be noted inadequate.
14 The overall survival in our investigation was
